Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIVERSYTI: CHF 5993 vs Symbicort in COPD
NCT03197818Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2016
- Primary completion
- May 2020
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Forced Expiratory Volume in the first second at 24 weeks. Started Dec 2016; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03197818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197818.